Neuronetics shares surge 10.37% premarket after Wall Street Zen upgrades rating to Hold from Sell.

Neuronetics surged 10.37% in premarket trading following an analyst upgrade from Wall Street Zen, which raised its rating from "Sell" to "Hold." This move occurred after the stock closed at its annual low of $1.35 on Friday, reflecting renewed cautious optimism amid extreme valuation divergences. While the company’s Q3 results showed a $0.13 loss per share and revenue below forecasts, the upgrade suggests analysts are beginning to price in potential stability, particularly as institutional investors like UBS and Goldman Sachs have increased holdings. The premarket rally aligns with the "Hold" rating’s implication that the worst of the downward momentum may be reflected in the price, despite ongoing fundamental challenges such as a -33.88% net margin and a 2026 CEO transition. The stock’s bounce highlights market speculation that professional investors are positioning for longer-term opportunities beyond current operational struggles.